Myriad Genetics, Inc. (MYGN) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 36 analysts14.9% Below Target
MYGN trades 14.9% below Wall Street's consensus target of $6.00.
Current Price$5.22
Average Target$6.00
Low$6.00
Median$6.00
High$6.00
Analyst Target Range
Forward P/E85.2x
(High Premium)
PEG Ratio—
Implied Growth+101.4%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes MYGN achieves its forward estimates and maintains a stable P/E multiple of 85.2x. This scenario reflects the blended consensus of 36 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
MYGN Price Target Analysis
Updated June 25, 2026As of June 25, 2026, Myriad Genetics, Inc. (MYGN) has a Wall Street consensus price target of $6.00, based on estimates from 36 covering analysts. With the stock currently trading at $5.22, this represents a potential upside of +14.9%. The company has a market capitalization of $488M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 8 analysts rating the stock as a Buy or Strong Buy,22 rating it Hold, and 6 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, MYGN trades at a trailing P/E of -1.3x and forward P/E of 85.2x. Analysts expect EPS to grow +101.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
-4.9%
Industry Consensus
Avg Forward P/E
118.3x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NTRANatera, Inc. | $37.2B | $259.97 | $259.88 | -0.0% | Buy | — | 27 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 VCYTVeracyte, Inc. | $4.5B | $56.76 | $47.60 | -16.1% | Buy | 31.0x | 20 |
 CDNACareDx, Inc | $1.4B | $27.13 | $27.00 | -0.5% | Buy | 29.0x | 13 |
 ILMNIllumina, Inc. | $26.6B | $175.09 | $151.40 | -13.5% | Buy | 33.5x | 50 |
 PACBPacific Biosciences of California, Inc. | $447M | $1.44 | $1.00 | -30.6% | Buy | — | 18 |
 GHGuardant Health, Inc. | $18.2B | $136.96 | $147.00 | +7.3% | Buy | — | 30 |
 FLGTFulgent Genetics, Inc. | $543M | $19.13 | $15.00 | -21.6% | Buy | — | 9 |
 LHLabcorp Holdings Inc. | $21.8B | $265.18 | $311.33 | +17.4% | Buy | 14.7x | 35 |
 DGXQuest Diagnostics Incorporated | $22.5B | $203.11 | $220.57 | +8.6% | Hold | 18.9x | 34 |
MYGN — Frequently Asked Questions
Quick answers to the most common questions about buying MYGN stock.
What is the MYGN stock price target for 2026?
Myriad Genetics, Inc. (MYGN) has a consensus 12-month price target of $6, implying 14.9% upside from $5.22. The 36 analysts covering MYGN see moderate appreciation potential.
Is MYGN a buy, sell, or hold?
MYGN has a consensus rating of "Hold" based on 36 Wall Street analysts. The rating breakdown is mixed, with 22 Hold ratings making up the largest segment. The consensus 12-month price target of $6 implies 14.9% upside from current levels.
Is MYGN stock overvalued or undervalued?
At a forward P/E of 85.155x, MYGN trades at a premium valuation. The consensus price target of $6 (14.9% upside) suggests analysts still see growth justifying the multiple.
How high can MYGN stock go?
The most bullish Wall Street analyst has a price target of $6 for MYGN, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MYGN stock?
MYGN is heavily covered by Wall Street, with 36 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 22 recommend Hold, and 6 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MYGN stock forecast?
The 12-month MYGN stock forecast based on 36 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Hold".
What is MYGN's forward P/E ratio?
MYGN trades at a forward P/E ratio of 85.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy MYGN stock?
Wall Street analysts are optimistic on MYGN, with a "Hold" consensus rating and $6 price target (14.9% upside). 8 of 36 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MYGN price targets vary so much?
MYGN analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare